Pegcetacoplan is a Synthetic peptide, Cyclic Peptide targeting C3, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Inebilizumab-cdon is a Monoclonal antibody targeting CD19, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Lunsekimig: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Zerlasiran is a siRNA targeting Lp(a), at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Masupirdine(Suven Life Sciences Ltd.): Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Sigvotatug vedotin: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Fosgonimeton: Suspended. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Trontinemab is a Bispecific antibody targeting APP x TfR1, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Zoldonrasib is a Non-degrading molecular glue targeting KRAS G12D, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Muvalaplin is a Small molecule drug targeting Lp(a), at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Zoliflodacin is a Small molecule drug targeting Bacterial Top II, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Zodasiran is a siRNA targeting ANGPTL3, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.